
By the end of this week, Moderna Therapeutics is likely to pull off the biggest initial public offering in biotech history, a $500 million fundraise with sweeping implications for the company, its innovative science, and the drug business as a whole.
Before Moderna — and its audacious plan to upend the industry — tests Wall Street’s appetite, here’s a guide to the outstanding questions pegged to biotech’s most scrutinized unicorn.
As expected, Moderna stock falls from its IPO price on the first day of trading. https://news.alphastreet.com/moderna-nasdaq-mrna-stock-raises-over-600-million-through-ipo-to-debut-on-friday/